The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases

Title:The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases

Volume: 16 Issue: 1

Author(s): Botond Penke*, Livia Fulop , Maria Szucs and Ede Frecska

Affiliation:

• University of Szeged, Department of Medical Chemistry, Faculty of Medicine, Szeged,Hungary

Keywords: Neurodegenerative diseases, sigma-1 receptor, pharmacology, agonist, DMT, antagonist, chaperone.

Abstract: Background: Widespread protein aggregation occurs in the living system under stress or during aging, owing to disturbance of endoplasmic reticulum (ER) proteostasis. Many neurodegenerative diseases may have a common mechanism: the failure of protein homeostasis. Perturbation of ER results in unfolded protein response (UPR). Prolonged chronical UPR may activate apoptotic pathways and cause cell death.

Methods: Research articles on Sigma-1 receptor were reviewed.

Results: ER is associated to mitochondria by the mitochondria-associated ER-membrane, MAM. The sigma-1 receptor (Sig-1R), a well-known ER-chaperone localizes in the MAM. It serves for Ca2+-signaling between the ER and mitochondria, involved in ion channel activities and especially important during neuronal differentiation. Sig-1R acts as central modulator in inter-organelle signaling. Sig-1R helps cell survival by attenuating ER-stress. According to sequence based predictions Sig-1R is a 223 amino acid protein with two transmembrane (2TM) domains. The X-ray structure of the Sig-1R [1] showed a membrane-bound trimeric assembly with one transmembrane (1TM) region. Despite the in vitro determined assembly, the results of in vivo studies are rather consistent with the 2TM structure. The receptor has unique and versatile pharmacological profile. Dimethyl tryptamine (DMT) and neuroactive steroids are endogenous ligands that activate Sig-1R. The receptor has a plethora of interacting client proteins. Sig-1R exists in oligomeric structures (dimer-trimer-octamer-multimer) and this fact may explain interaction with diverse proteins.

Conclusion: Sig-1R agonists have been used in the treatment of different neurodegenerative diseases, e.g. Alzheimer's and Parkinson's diseases (AD and PD) and amyotrophic lateral sclerosis. Utilization of Sig-1R agents early in AD and similar other diseases has remained an overlooked therapeutic opportunity.

Cite this article as:

Penke Botond *, Fulop Livia , Szucs Maria and Frecska Ede , The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases, Current Neuropharmacology 2018; 16 (1) . https://dx.doi.org/10.2174/1570159X15666170529104323